Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The free forumotion site received four new requests to login this morning. At the top of the login page is a statement that reads "Pre-Registration: Please use the contact below to send a note with some basic information about yourself, such as name, alias(es), email, where you're from and such. Thanks."
While the forum respects and even encourages a diversity of opinions and healthy debate and accepts the fact that some negative comments are inevitable, it will not tolerate mindless bashing. To protect the security and confidential nature of the site we need to know the membership.
Thank you.
OT: Bucky
It's my local hill. Nice people there, we always have a course set up or something going on to make a little bump by the side of the road fun. 110 instructors. Lots of guys from your neck of the woods. Plymouth, Port W, etc. We all play the Irish in the spring/fall when they have specials.
I recognize your signature from the old RB days. Years ago I went to several of the annual meetings in Denver and would meet with Dooper. Small world. Nice to see you here.
do
Ot: Hey Bucky, you're right. The last 2 early seasons at W-B were great and the one before that was a total bust, even higher up. If you can make last minute plans you can hit great snow early with no crowds but if you tie in early you may be stuck some place you'd rather not be.
Do you ever get over to Sunburst?
Hey Humm, here's a site that explains the listing requirements for the various exchanges.
http://www.venturelawcorp.com/listing_requirement_master_chart.htm
Only 7 months until the hills reopen.
Who you know helps but it takes a successful resume. It's good to see an outside director added.
NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director
Tuesday April 8, 9:45 am ET
HUBBARD, Ohio, April 8, 2008 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC Pink Sheets: NNLX - News) a nano-biotechnology company announces publication of 2007 financial data and a director appointment.
NanoLogix has posted 2007 unaudited financials. 2007 expenditures were reduced by 42% over 2006, while funding for 2007 Research and Development was increased by 19%. The information can be accessed at: http://www.nanologixinc.com/financials.html
NanoLogix welcomes Bert Pharis to the Board of Directors. Mr. Pharis was formerly President and CEO of Sygnet Wireless, a Cellular Telephone Company in Northeastern Ohio and Western Pennsylvania, from the mid-Eighties until Sygnet's 1998 sale to Dobson Communications. Mr. Pharis then served as a Director of Dobson Communications, sitting on both the Audit and Compensation Committees, through the 2007 sale of Dobson to AT&T. He was President and CEO of Logix Communications, a Competitive Local Exchange Carrier operating primarily in Texas and Oklahoma, from 1999 through 2001. Following that he spent two years as President and CEO of Ortheon Medical, a Medical Device Company in Orlando, Florida.
Bret Barnhizer, CEO of NanoLogix stated, "Bert Pharis is a welcome addition to our new Board of Directors, bringing extensive corporate business expertise in addition to experience with the processes involved in obtaining FDA approval for medical devices."
They are still around but no one is beating down their door.
http://www.hytechapps.com/
There were two things that stood out in the video. First was that he didn't say how much electrical energy was expended in the conversion process. And the second was that he got 100 miles on 4 ounces of water.
Hi Hum. I don't want to distract this NNLX forum with delving into US economic policy aside from saying that a move away from the level of energy dependence that we have would be a major part of evening the trade deficit. We can do that in many ways from opening more domestic areas to drilling, conservation, mass transit, more efficient building design, more efficient urban planning, and alternate energy production including solar, wind, hydroelectric, geothermal, coal to liquid, cellulosic ethanol and biomass conversion including the NNLX process. And there are of course many many more.
That said I am looking forward to news regarding a commercial application of the NNLX process. The snow is gone in Erie PA and construction should be starting on the bioreactor at the municipal waste water treatment plant. If they can build a commercially viable hydrogen bioreactor it will be one of many small steps in helping the economy and the environment. But far more importantly it will give the share price a nice goose.
NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
Monday March 31, 9:45 am ET
HUBBARD, Ohio, March 31 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC: NNLX - News) a nano-biotechnology company is pleased to provide the following updates on company events:
NanoLogix personnel are manning a booth and presenting at the National Hydrogen Association Expo in Sacramento this week, with the company being represented by William Hartman and Chris Novak. Mr. Hartman will be presenting in the Exhibition Hall today, March 31, from 2:00-2:30 pm, on "Biohydrogen and Electricity Production from Waste Water".
Company CEO Bret Barnhizer was Marlene Bourne's guest on The Bourne Report March 16, on the topic of Hydrogen Power. The interview provides updates on hydrogen bioreactor operations. Access: http://www.bournereport.com/radio.php
Work on BNC and BNP development for fast microorganism detection is proceeding at a rapid pace, with a new patent application filed in March and positive developments with both the Departments of Defense and Homeland Security in late February.
Director and Management changes: Dr. Robert Ollar and John Chatterton have joined the Board of Directors. Dr. Ollar is cofounder of NanoLogix (as Infectech), the primary author of the majority of the company's granted patents, and returns to the company after a six year hiatus. Mr. Chatterton is former co-host of the History Channel series, Deep Sea Detectives, and is one of the world's most accomplished and well known underwater explorers. David Barnhizer has joined the company as General Counsel, bringing to the company nearly forty years of legal expertise. Detailed director and management team information can be accessed at: http://www.nanologixinc.com/index-2.html
General Counsel David Barnhizer stated: "NNLX is poised to make a significant move forward under its new board of directors and management team headed by CEO and Board Chairman Bret Barnhizer and complemented by a reformed and greatly strengthened board of directors. A skilled and knowledgeable team of professionals whose members are fully dedicated to the advancement of NanoLogix has been put into place. As NNLX General Counsel I am extremely pleased to be associated with a group of professionals committed to the building of an exceptional company whose patented technologies are on the cutting edge of hydrogen energy extraction from industrial and commercial wastes, as well as diagnostic tools that are drawing the attention of governmental and commercial institutions."
The company has accepted the resignations of directors Hartman, Allan, and Cavallo from all positions held. Mr. Hartman will continue to provide business consulting services to NanoLogix.
Actually 3 new names added to the corporate masthead in the last week or so. John Chatterton, Robert Ollar, and David Barnhizer.
http://www.nanologixinc.com/index-2.html
Chris Novack joined the company August 27th, 2007.
http://www.nanologixinc.com/pr-8-27-07-Director-Anthrax.htm
One year anniversary. Eom
Old news: Virgin Fuels has committed more than four hundred million dollars, for research into the feasibility of using enzymes and genetically modified organisms to produce green fuels. Richard Branson is doing this in search of economic opportunity as his first priority. There is a race, and as we have seen with ethanol, efficiency and common sense often take a back seat to politics and big money.
http://www.virgin-fuels.net/
Ted, not that I know of. Sorry. eom
Those are reports of old infectech paper filings. I never requested them. Old news.
Designer Diagnostics Begins Marketing First Ever Environmental Test Kit for the Detection of Nontuberculous Mycobacteria
Monday February 25, 9:00 am ET
BOCA RATON, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp. (OTCBB:NPHC - News), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has today announced that its wholly-owned medical devices subsidiary, Designer Diagnostics, has started marketing the first-ever environmental test kit for the detection of Nontuberculous Mycobacteria (NTM) in water and soil.
The primary goal of these environmental test kits is to reduce the number of NTM infections worldwide by preventing the public’s exposure to NTM and determining the source of origin of NTM infections in patients,” explained Neil Roth, President of Designer Diagnostics. “In order to accomplish this goal, we believe that every municipality, hospital and water treatment facility should have these test kits on hand for periodic testing of the environment,” he added.
Nontuberculous Mycobacterium, also known as atypical Tuberculosis (Atypical TB) or Mycobacterium other than Tuberculosis (MOTT), is a bacteria that is found in a multitude of environments - in the soil, in some domestic and wild animals, and perhaps most importantly, in water, including showers and hot tubs. One of the most common forms of NTM infections found in humans is Mycobacterium avium complex (MAC). This is a primary cause of respiratory disease in humans and is a leading cause of death in HIV/AIDS patients.
In December, Nutra Pharma announced that it expanded its licensing agreement with Ohio-based NanoLogix, Inc. (PINK SHEETS:NNLX - News) to include additional intellectual property for the use of testing the environment for NTM.
“All of us at NanoLogix are excited that this beneficial technology is finally coming to market,” said Bret Barnhizer, CEO of NanoLogix, Inc. “These test kits will not only play an important role in reducing NTM infections in developing nations, but will also assist in the detection and prevention of NTM exposure and infection in the United States and other developed countries,” he added.
Recently, distinguished NTM research scientist Dr. Rahul Narang used the Designer Diagnostics environmental test kits to test soil and water samples collected from the environment of patients with NTM infections. This was the first time the technique was used in India and the findings were presented in November at the 38th Union World Conference on Lung Health in Cape Town, South Africa.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp., through its subsidiaries, carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.DesignerDiagnostics.com
Although it may be too early for on-site construction they should be working on, or finished with, front end engineering and design work. They should have contracts out for bid and they should have financing in place. Most of the bioreactor is made offsite and that work should be starting soon if it hasn't already. They signed the agreement with Erie to build this thing a year and a half ago. I realize they initially had some problems like reforming the sludge into a product more accessible to the bacteria but I thought they had worked through those things. When the weather breaks they should do the site work, assemble the bioreactor, do the construction and hook it up.
There may be interest in the bioreactor but there is certainly no interest in the stock. We should be getting a PR on the Welch project along with updates on Welch & Erie regarding FEED, financing, contracts etc. Real projects with real potential.
Monday January 28, 10:00 am ET
HUBBARD, Ohio, Jan. 28 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC: NNLX - News) a nano-biotechnology company is pleased to announce that its hydrogen-from-waste extraction technology currently under development at a Welch's juice plant in Pennsylvania has been the focus of a broadcast article by "The Allegheny Front" - Environmental Radio for Western Pennsylvania". The broadcast was produced by Lisa Ann Pinkerton and aired January 23rd on WYEP- FM, a listener-supported public radio station in Pittsburgh. The archived broadcast can be accessed at: http://alleghenyfront.org/index.html and is titled as both "Microbes Turn Waste to Power" and "Welch's Grape Juice Converted into Electricity".
New on the NNLX website:
Thursday, January 17: The recording of our annual Shareholder Meeting held on December 28th, 2007 at 1PM, EST. is now available at this link.
http://www.nanologixinc.com/DS300002_1.wma
I doubt that any investor with a long term perspective would think twice about the PR. I have noticed in the last few days that NNLX has popped up on my automatic google alerts quite a few times as the story gets wider circulation. Both in the conventional press and blogs.
They have been able to stay in business for 20 years and they are closer to commercialization then they have ever been. I don't see the credit markets closing off at this time.
A lot of noise about very little. This is a penny stock and almost no one takes them seriously. Any positive publicity is good for it. Anything that will raise the price is good in that it will actually lower the amount of dilution. A company like Apple has 27 analysts (currently) following and commenting on their every move. NNLX does not have that luxury.
That said I'm looking forward to hearing something more substantial from the company. Soon.
This is a copy of the proxy. The formatting changes when posting here but the idea is that you can vote for all, some or none of the directors as you choose.
December 5, 2007
NANOLOGIX, INC. Annual Meeting
Meeting Date: 12/28/2007 for holders as of 11/23/2007
CUSIP: xxxxxxxxx Your Control Number: xxxxxxxxxx
If you plan to attend the meeting Click here.
Meeting Materials
Proxy Statement
As your vote is very important, we recommend that all voting instructions be received at least one business day prior to the voting cut-off time stated in the information circular. Scroll down for proxy instructions and voting.
Scroll down for proxy instructions and voting.
Proxy Ballot:
Directors' Recommendations:
Choose this if you would like to vote your shares following directors' recommendations.
See below or refer to the proxy statement for the detailed recommendations. Please read them carefully.
Vote
01. DIRECTOR(S):
Directors Recommend a vote FOR election of the following nominee(s):
(1) BRET T. BARNHIZER (2) DANA ALLEN (3) ANTHONY P. CAVALLO
(4) WILLIAM A. HARTMAN
For all nominees Withhold all nominees For all EXCEPT those selected below
BRET T. BARNHIZER
DANA ALLEN
ANTHONY P. CAVALLO
WILLIAM A. HARTMAN
Vote my shares as per the above selections
Legal Proxy:
Choose this only if you plan to attend and vote your shares at the meeting.
IMPORTANT: By choosing this option, we are precluded from voting your shares on your behalf. A Legal Proxy covering your securities will be issued to you. Your Legal Proxy must be presented at the meeting for your shares to be represented. Do not make any other marks on this ballot.
DO NOT use this option if you hold shares directly with the issuer, rather than through a bank or broker.
Click to see: "Letter to our clients regarding voting authority"
Back to top
Download Adobe® Reader® l Privacy Statement
This morning I received my proxy via e-mail from my broker. Your vote must be received at least a day before the meeting so you still have 3 weeks to get it in the mail and respond. The mailing will probably have instructions for voting on the phone or internet also.
There is only one item in the proxy to vote on and that is for the directors.
Thanks, I saw that. The testing/diagnostic business is huge. I don't think this is competition. I'm not sure what it tests but it's not bacteria.
December 28th is the ASM. Are any IH-ites planning on going?
NanoLogix Inc. Files Multiple International Patent Applications for BioNanoChannel(TM) and Hydrogen Bioreactor Technology
Wednesday November 28, 10:00 am ET
HUBBARD, Ohio, Nov. 28 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC: NNLX - News) a nano-biotechnology company announces that the company has submitted international patent applications for BioNanoChannel(TM) and Hydrogen Bioreactor technology protection for China, India, Brazil, and the EU (European Union). These filings are necessary prior to the anticipated global roll-out of the company's BioNanoChannel(TM) rapid bacteria/microorganism detection technology and also contribute to the protection of NanoLogix's ongoing Hydrogen Bioreactor development.
Chris Novak, NanoLogix Director of IP stated: "The strength and improved focus of the new foreign cases arose from significant improvements to the originally filed provisional patent applications. We at NanoLogix are very excited about the potential for enhancing the patent protection for these new technologies."
According to Bret Barnhizer, NanoLogix President and CEO, "This is a step forward for the company in its plans for technological and business development and sets the stage for one of our corporate goals of pursuing licensing opportunities for use of our products internationally. These applications aid us by ensuring that NanoLogix strengthens their control over the intellectual property rights to the technology."
Nutra Pharma Announces Publication of Test Kit Technology in the International Journal of TB and Lung Diseases
Monday November 19, 9:00 am ET
BOCA RATON, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp. (OTCBB:NPHC - News), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis(MS), has today announced that its wholly owned subsidiary, Designer Diagnostics, Inc., will be featured in an upcoming article published in the International Journal of TB and Lung Diseases. The article, which is authored by leading NonTuberculous Mycobacterium (NTM) research scientist, Dr. Rahul Narang, will cover Designer Diagnostics’ paraffin culture technology to isolate NTM.
The International Journal of TB and Lung Diseases is an important and well-respected publication covering all topics related to lung health,” explained Neil Roth, President of Designer Diagnostics. “This article will act as an important stepping-stone in helping to build awareness about the importance of the Designer Diagnostics technology to isolate NTM,” he added.
Recently, Dr. Narang presented the Designer Diagnostics test kit technology at the 38th Union World Conference on Lung Health in South Africa. Dr. Narang’s presentation included information about the Designer Diagnostics test kits use in isolating NTM from clinical samples of 300 AIDS patients. The presentation also announced that for the first time ever on the Indian subcontinent, M. wolinskyi, a rapidly growing mycobacteria that is most commonly seen in post-traumatic wound infections and in immune-compromised patients, was successfully isolated in clinical samples.
“NTM infection is a serious health issue affecting millions of people each year in developing countries. Especially those countries with high incidence rates of HIV,” commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “We believe that the Designer Diagnostics test kits are vital for early diagnosis of the infection in patients, as the test kits are faster and less expensive than current tests. These kits are perfect for developing countries as they can be used in the field without the need for refrigeration and expensive lab equipment,” he concluded.
Good recap Mr. Moe, thanks. eom
WallSt.net (www.wallst.net) Announces Upcoming Interview With Chairman, President and CEO of NanoLogix, Inc.
Monday November 5, 7:00 am ET
NEW YORK, Nov. 5 /PRNewswire/ -- Bret Barnhizer, Chairman, CEO and President of NanoLogix, Inc. (Pink Sheets: NNLX - News; www.nanologixinc.com) will be featured in an exclusive interview with www.wallst.net that is scheduled to take place on November 7, at 11 a.m. EST. The interview will be posted on www.wallst.net by 8 p.m. EST on November 7.
The interview will cover topics including NanoLogix's market potential, growth initiatives, competitive edge, recent news, and milestones for investors to watch for.
To hear the interview in its entirety, visit http://www.wallst.net, and click on "Interviews." The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange on the at the top of the "Interviews" section of the site, or by entering the company's ticker symbol in the Search Archive window on the right-hand column of the "Interviews" section once it is posted.
On Oct 10th they said "NanoLogix plans to also release Quarterly Financials for 2007 through the Third Quarter (September 30th, 2007) in October." They were probably told by their accountants that the financial would be done by then. I would expect them in the next day or two or at least by the end of the week. If there is a delay they will probably update us on their web site. They have been pretty good at comunicating.
This is a much different company than it was a year ago and the way everything is progressing the company will be substantially different in a year from now.
I wish I could get to the ASM but I already have plans. I’m sure that someone on this board will be there and relay their impressions to us. We should also have some questions prepared for the Q & A following the meeting.
NanoLogix Inc. Sets Date for Annual Shareholder Meeting and Provides Shareholder Update
Tuesday October 30, 9:45 am ET
HUBBARD, Ohio, Oct. 30 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC Bulletin Board: NNLX - News) a nano-biotechnology company announces the date and venue for the Company's annual shareholder meeting.
The meeting will take place at 1 PM on 12/28/07 and will be held at the Company's Hubbard, Ohio office. A call-in number will be provided for questions to management. The number will be made available on our website two days prior to the meeting. Shareholders of record as of 11/23/07 will receive proxy statements.
Research and development continues with the prototype bioreactor at Welch's, with design and economic modeling proceeding for construction of the next generation of hydrogen bioreactors for both Welch's and the Erie Wastewater Treatment Plant projected installations. State and Federal grant assistance is being explored and pursued for both Pennsylvania and Ohio operations.
Testing for Department of Defense anthrax decontamination confirmation has been completed successfully and NanoLogix is currently working on additional BioTerrorism issues, such as toxin identification.
The Board of Directors met on 10/22/07, with a majority of directors passing a motion to reduce director and executive stock compensation by 50%. Coupled with a 50% reduction last March, this measure reduced the maximum shares awardable annually to any one individual from 2,000,000 to 500,000. Bret Barnhizer, CEO and President, stated, "This measure accomplishes this year's goal of reducing compensation-related dilution. Every share issued to directors and executives is a share that is not available for use in raising capital necessary for research and development and operational expenses. This management team is committed to NanoLogix's future and believes in the philosophy of building company value over the long term."
On raising capital, Dana Allen, Vice President for Strategic Partnering said: "NanoLogix is currently pursuing multiple strategies for funding: existing revenue from patent royalties, developing sales of BioNanoChannel(TM) technology, pursuing grant funding, strategic partnering with companies in our technology sectors, and lastly, through private investment. This private investment approach is focused on providing stability to the share price, and is designed to partner with investors who have a long term view of the company and its prospects. We have been successful in this approach over the last four months and have raised capital from a group of accomplished Silicon Valley private investors. Ultimately, we are looking forward to the time when revenue and cash flow will be the sole funding mechanism for the Company."
Eventually there will be a press release, a conference call, an annual shareholders meeting or a 10K that will flesh out the numbers. In lieu of that anyone can call the company and ask.
The numbers were better, or at least not as bad, as I had expected. I'm impressed with the timing also. Good work.
NNLX website update:
October 8, 2007, NanoLogix, Inc. is pleased to announce it has completed its audit through 2004. They are available for viewing at this link (NanoLogix Financials). They included a statement of Stockholders Equity/Deficit for 1989 through 2003 and complete financials for 2003 and 2004. This week, NanoLogix plans to also release complete financials for 2005 and 2006. That will be followed by Quarterly Financials for 2007 up through the Third Quarter (September 30th, 2007). The company plans to accomplish this in October.
The audit was performed by Blocksom and Associates. This accomplishes another step in NanoLogix's plan to be fully reporting to it's shareholders.
http://www.nanologixinc.com/
Mike, if a company does a reverse split it can choose to cash out smaller shareholders if it wishes and the company can decide what is a small shareholder. If you call or e-mail NNLX and ask I'm fairly certain the answer you will get is that they are not even considering a reverse split.
Not yet, we're still waiting. (eom)
Hummingbird! Congratulations! (eom)
A reverse split is not a feasible strategy for getting NNLX onto the Nasdaq. While it would raise the $/share in the short term it would not help to meet the other listing requirements such as the minimum two year average pre-tax income level or the shareholders equity values.